eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
1/2012
vol. 50
 
Share:
Share:
more
 
 
abstract:
Review paper

The role of anticentromere antibodies in diagnosis of rheumatic and cancer diseases

Joanna Pyka
,
Iwona Horbacz
,
Elwira Biernacka
,
Jakub Ząbek

Reumatologia 2012; 50, 1: 52–56
Online publish date: 2012/03/02
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Autoantibodies to centromere proteins (CENPs) were first described in 1980 in limited cutaneous SSc (lcSSc) patients. Since that time a number of CENPs have been identified as autoantibody targets in many rheumatic and cancer diseases (Table I, Fig. 1). The general method for detection of anti-centromere antibodies (ACA) is indirect immunofluorescence using HEp-2 cell slides. Autoantibodies CENP-A, -B, -C are relatively specific biomarkers for lcSSc (CREST syndrome). This review focuses on updating information on CENP antibodies against particular autoantigens and their new clinical associations: anti-CENP-A with early Ssc, anti-CENP-D IgM with SLE + Sjögren syndrome, anti-CENP-H (in SSA/SSB negative patients) and anti-CENP-C with Sjögren syndrome. Anti-CENP-F antibodies have totally different clinical significance and occur mainly in cancer diseases.
keywords:

anti-centromere antibodies, centromere proteins, cell division cycle



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe